Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9 that is selective over the cathepsins as well as other protease families, displays good metabolic stability and permeability, oral bioavailability and low cytochrome P450 (CYP) inhibition. It is under development for the treatment of coronavirus disease-19 (COVID-19) resulting from infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2), where there is significant unmet medical need.
Description: To evaluate time to recovery as defined by no longer requiring oxygen support or hospital discharge, whichever occurs first.
Measure: Time to recovery Time: Course of study; 28 daysDescription: To evaluate change in oxygenation in hospitalized adults with COVID-19 treated with BLD-2660. Measured by change from baseline to Day 10 or hospital discharge, if sooner, in the ratio of peripheral hemoglobin oxygen saturation to fraction of inspired oxygen (SpO2/FiO2)
Measure: Change in oxygenation Time: 10 daysDescription: To evaluate the safety and tolerability of BLD-2660 in the same population. Measured by incidence of TEAEs and serious adverse events (SAEs)
Measure: Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs) Time: Course of study; 28 daysDescription: To evaluate change in oxygenation while hospitalized & during follow-up visits. Measured by: Improvement from baseline to Days 10, 14, 21 and 28 as measured by the ratio of hemoglobin oxygen saturation to inspired oxygen fraction (SpO2/FiO2), categorized on the 4-point ordinal scale Time to discontinuation of oxygen supplementation requirement Mean SpO2 for subjects not requiring oxygen supplementation at Days 5, 10, 21 and 28 Number of O2 supplementation free days during hospitalization Proportion of subjects who do not require oxygen supplementation (sustained for at least 24 hours) during hospitalization
Measure: Change in oxygenation Time: Course of study; 28 daysDescription: Measured by mortality rate during the 28-day study period following enrollment.
Measure: Rate of mortality Time: Course of study; 28 daysDescription: Measured by time to discharge readiness
Measure: Time to discharge readiness Time: Course of study; 28 daysDescription: Measured by proportion of subjects ready to be discharged from the hospital during the 28-day study period following enrollment.
Measure: Proportion of subjects discharged during study Time: Course of study; 28 daysDescription: Measured by proportion of subjects with resolution of fever below entry criteria for 24 hours by Day 10 in subjects with fever at baseline
Measure: Proportion of subjects with resolved fever Time: 10 daysDescription: Measured by time to resolution of fever below entry criteria for 24 hours in subjects with fever at baseline
Measure: Time to resolution of fever Time: Course of study; 28 daysDescription: Measured by duration (in days) of remdesivir use in subjects starting remdesivir within 24 hours of first dose of BLD-2660
Measure: Duration of Remdesivir use Time: Course of study; 28 daysDescription: Measured by change from baseline to Days 10, 14, 21 and 28 in clinical status outcome using a 6-point ordinal scale
Measure: Change in clinical status Time: Course of study; 28 daysDescription: Measured by proportion of subjects reporting each 6-point ordinal scale of the clinical status outcome assessment.
Measure: Proportion of subjects in each category of the 6-point ordinal scale Time: Course of study; 28 daysDescription: Measured by change from baseline to Days 5, 10, 14, 21 and 28 in NEWS score
Measure: Change from in NEWS score Time: Course of study; 28 daysDescription: Measured by change from baseline to Days 10, 14, 21 and 28 in IL-6 in ng/mL measured by analytical assay
Measure: Change in IL-6 Time: Course of study; 28 daysDescription: Measured by change from baseline to Days 10, 14, 21 and 28 in D-dimer in ng/mL measured by analytical assay
Measure: Change in D-dimer Time: Course of study; 28 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports